These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

221 related articles for article (PubMed ID: 25882246)

  • 41. Striatal, Hippocampal, and Cortical Networks Are Differentially Responsive to the M4- and M1-Muscarinic Acetylcholine Receptor Mediated Effects of Xanomeline.
    Thorn CA; Moon J; Bourbonais CA; Harms J; Edgerton JR; Stark E; Steyn SJ; Butter CR; Lazzaro JT; O'Connor RE; Popiolek M
    ACS Chem Neurosci; 2019 Mar; 10(3):1753-1764. PubMed ID: 30480428
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Evidence for Classical Cholinergic Toxicity Associated with Selective Activation of M1 Muscarinic Receptors.
    Alt A; Pendri A; Bertekap RL; Li G; Benitex Y; Nophsker M; Rockwell KL; Burford NT; Sum CS; Chen J; Herbst JJ; Ferrante M; Hendricson A; Cvijic ME; Westphal RS; O'Connell J; Banks M; Zhang L; Gentles RG; Jenkins S; Loy J; Macor JE
    J Pharmacol Exp Ther; 2016 Feb; 356(2):293-304. PubMed ID: 26582730
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Functional comparison of muscarinic partial agonists at muscarinic receptor subtypes hM1, hM2, hM3, hM4 and hM5 using microphysiometry.
    Wood MD; Murkitt KL; Ho M; Watson JM; Brown F; Hunter AJ; Middlemiss DN
    Br J Pharmacol; 1999 Apr; 126(7):1620-4. PubMed ID: 10323594
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Contrasting effects of allosteric and orthosteric agonists on m1 muscarinic acetylcholine receptor internalization and down-regulation.
    Thomas RL; Langmead CJ; Wood MD; Challiss RA
    J Pharmacol Exp Ther; 2009 Dec; 331(3):1086-95. PubMed ID: 19767446
    [TBL] [Abstract][Full Text] [Related]  

  • 45. M1 receptor agonist activity is not a requirement for muscarinic antinociception.
    Sheardown MJ; Shannon HE; Swedberg MD; Suzdak PD; Bymaster FP; Olesen PH; Mitch CH; Ward JS; Sauerberg P
    J Pharmacol Exp Ther; 1997 May; 281(2):868-75. PubMed ID: 9152396
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Xanomeline compared to other muscarinic agents on stimulation of phosphoinositide hydrolysis in vivo and other cholinomimetic effects.
    Bymaster FP; Carter PA; Peters SC; Zhang W; Ward JS; Mitch CH; Calligaro DO; Whitesitt CA; DeLapp N; Shannon HE; Rimvall K; Jeppesen L; Sheardown MJ; Fink-Jensen A; Sauerberg P
    Brain Res; 1998 Jun; 795(1-2):179-90. PubMed ID: 9622623
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Action of the muscarinic toxin MT7 on agonist-bound muscarinic M1 receptors.
    Olianas MC; Adem A; Karlsson E; Onali P
    Eur J Pharmacol; 2004 Mar; 487(1-3):65-72. PubMed ID: 15033377
    [TBL] [Abstract][Full Text] [Related]  

  • 48. In Vivo Pharmacological Comparison of TAK-071, a Positive Allosteric Modulator of Muscarinic M
    Mandai T; Kasahara M; Kurimoto E; Tanaka M; Suzuki M; Nakatani A; Kimura H
    Neuroscience; 2019 Aug; 414():60-76. PubMed ID: 31299348
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Hybrid molecules from xanomeline and tacrine: enhanced tacrine actions on cholinesterases and muscarinic M1 receptors.
    Fang L; Jumpertz S; Zhang Y; Appenroth D; Fleck C; Mohr K; Tränkle C; Decker M
    J Med Chem; 2010 Mar; 53(5):2094-103. PubMed ID: 20158205
    [TBL] [Abstract][Full Text] [Related]  

  • 50. The highly efficacious actions of N-desmethylclozapine at muscarinic receptors are unique and not a common property of either typical or atypical antipsychotic drugs: is M1 agonism a pre-requisite for mimicking clozapine's actions?
    Davies MA; Compton-Toth BA; Hufeisen SJ; Meltzer HY; Roth BL
    Psychopharmacology (Berl); 2005 Apr; 178(4):451-60. PubMed ID: 15765260
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Comparative analysis of pharmacological properties of xanomeline and N-desmethylclozapine in rat brain membranes.
    Odagaki Y; Kinoshita M; Ota T
    J Psychopharmacol; 2016 Sep; 30(9):896-912. PubMed ID: 27464743
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Effects of muscarinic M
    Stoll K; Hart R; Lindsley CW; Thomsen M
    Psychopharmacology (Berl); 2018 Mar; 235(3):815-827. PubMed ID: 29250738
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Behavioral effects of N-desmethylclozapine on locomotor activity and sensorimotor gating function in mice-Possible involvement of muscarinic receptors.
    Maehara S; Hikichi H; Ohta H
    Brain Res; 2011 Oct; 1418():111-9. PubMed ID: 21917240
    [TBL] [Abstract][Full Text] [Related]  

  • 54. The assessment of antagonist potency under conditions of transient response kinetics.
    Christopoulos A; Parsons AM; Lew MJ; El-Fakahany EE
    Eur J Pharmacol; 1999 Oct; 382(3):217-27. PubMed ID: 10556673
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Pharmacological characterization of human m1 muscarinic acetylcholine receptors with double mutations at the junction of TM VI and the third extracellular domain.
    Huang XP; Williams FE; Peseckis SM; Messer WS
    J Pharmacol Exp Ther; 1998 Sep; 286(3):1129-39. PubMed ID: 9732369
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Molecular determinants of allosteric modulation at the M1 muscarinic acetylcholine receptor.
    Abdul-Ridha A; López L; Keov P; Thal DM; Mistry SN; Sexton PM; Lane JR; Canals M; Christopoulos A
    J Biol Chem; 2014 Feb; 289(9):6067-79. PubMed ID: 24443568
    [TBL] [Abstract][Full Text] [Related]  

  • 57. The muscarinic M1/M4 receptor agonist xanomeline exhibits antipsychotic-like activity in Cebus apella monkeys.
    Andersen MB; Fink-Jensen A; Peacock L; Gerlach J; Bymaster F; Lundbaek JA; Werge T
    Neuropsychopharmacology; 2003 Jun; 28(6):1168-75. PubMed ID: 12700711
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Dual effects of muscarinic M(2) acetylcholine receptors on the synthesis of cyclic AMP in CHO cells: dependence on time, receptor density and receptor agonists.
    Michal P; Lysíková M; Tucek S
    Br J Pharmacol; 2001 Mar; 132(6):1217-28. PubMed ID: 11250872
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Design and development of selective muscarinic agonists for the treatment of Alzheimer's disease: characterization of tetrahydropyrimidine derivatives and development of new approaches for improved affinity and selectivity for M1 receptors.
    Messer WS; Rajeswaran WG; Cao Y; Zhang HJ; el-Assadi AA; Dockery C; Liske J; O'Brien J; Williams FE; Huang XP; Wroblewski ME; Nagy PI; Peseckis SM
    Pharm Acta Helv; 2000 Mar; 74(2-3):135-40. PubMed ID: 10812950
    [TBL] [Abstract][Full Text] [Related]  

  • 60. A novel muscarinic receptor-independent mechanism of KCNQ2/3 potassium channel blockade by Oxotremorine-M.
    Zwart R; Reed H; Clarke S; Sher E
    Eur J Pharmacol; 2016 Nov; 791():221-228. PubMed ID: 27590358
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.